Polycystin-1, the product of the polycystic kidney disease gene PKD1, is post-translationally modified by palmitoylation
- 216 Downloads
Multiple distinct mutations in the protein polycystin 1 (PC1) cause autosomal dominant polycystic kidney disease (ADPKD), a common cause of end stage renal disease. Growing evidence supports the theory that the severity and rate of progression of kidney cysts is correlated with the level of functional PC1 expressed in the primary cilia. Factors that regulate trafficking of PC1 to cilia are thus of great interest both as potential causes of ADPKD, but also as possible modifiable factors to treat ADPKD. Cysteine palmitoylation is a common post-translational modification that frequently alters protein trafficking, localization, and expression levels. Here, using multiple complementary approaches, we show that PC1 is palmitoylated, likely at a single cysteine in the carboxyl terminal fragment that is generated by autoproteolysis of PC1. Additional data suggest that protein palmitoylation is important for PC1 localization and expression levels. These data together identify palmitoylation as a novel post-translational modification of PC1 and a possible pharmacologic target to augment PC1 expression in cilia.
KeywordsPalmitoylation Cilia Protein posttranslational modification Trafficking
This work was supported by a Pilot and Feasibility Grant from the Yale Polycystic Kidney Disease Center, funded by NIH P30 DK090744. We thank the Drs. Caplan and Somlo and members of their laboratories for helpful discussions.
Compliance with Ethical Standards
Conflict of interest
The authors have no conflicts of interest, financial or otherwise, to disclose. No animal nor human subjects were involved in the conduct of the research.
- 1.Besse W, Dong K, Choi J, Punia S, Fedeles SV, Choi M, Gallagher AR, Huang EB, Gulati A, Knight J, Mane S, Tahvanainen E, Tahvanainen P, Sanna-Cherchi S, Lifton RP, Watnick T, Pei YP, Torres VE, Somlo S (2017) Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest 127:1772–1785. https://doi.org/10.1172/JCI90129 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Cai Y, Fedeles SV, Dong K, Anyatonwu G, Onoe T, Mitobe M, Gao JD, Okuhara D, Tian X, Gallagher AR, Tang Z, Xie X, Lalioti MD, Lee AH, Ehrlich BE, Somlo S (2014) Altered trafficking and stability of polycystins underlie polycystic kidney disease. J Clin Invest 124:5129–5144. https://doi.org/10.1172/JCI67273 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Fedeles SV, Tian X, Gallagher AR, Mitobe M, Nishio S, Lee SH, Cai Y, Geng L, Crews CM, Somlo S (2011) A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat Genet 43:639–647. https://doi.org/10.1038/ng.860 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC (2012) Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122:4257–4273. https://doi.org/10.1172/JCI64313 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, Deruiter MC, Breuning MH, de Heer E, Peters DJ (2004) Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13:3069–3077. https://doi.org/10.1093/hmg/ddh336 CrossRefPubMedGoogle Scholar
- 7.Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Banales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrezet MP, Ferec C, Le Meur Y, Torres VE, Genkyst Study Group HPoPKDG, Consortium for Radiologic Imaging Studies of Polycystic Kidney D, Harris PC (2016) Mutations in GANAB, encoding the glucosidase II alpha subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193–1207. https://doi.org/10.1016/j.ajhg.2016.05.004 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, Cai Y, Kamath PS, King BF, Azurmendi PJ, Tahvanainen P, Kaariainen H, Hockerstedt K, Devuyst O, Pirson Y, Martin RS, Lifton RP, Tahvanainen E, Torres VE, Somlo S (2004) Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 36:575–577. https://doi.org/10.1038/ng1357 CrossRefPubMedGoogle Scholar
- 23.Dekker FJ, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Scholermann B, Rusch M, Kramer JW, Rauh D, Coates GW, Brunsveld L, Bastiaens PI, Waldmann H (2010) Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat Chem Biol 6:449–456. https://doi.org/10.1038/nchembio.362 CrossRefPubMedGoogle Scholar